Synthesis of A New Gedatolisib Derivative

Project no. 33317 · Status: Kapanmış · 2025

Summary

<p> 1,3,5-triazine,&nbsp;also&nbsp;called&nbsp;s-triazine,&nbsp;is&nbsp;one&nbsp;of&nbsp;the&nbsp;important&nbsp;srating&nbsp;materials&nbsp;widely&nbsp;used&nbsp;in&nbsp;the&nbsp;pharmaceutical&nbsp;chemistry.&nbsp;s-triazine&nbsp;compounds&nbsp;possess&nbsp;significant&nbsp;biological&nbsp;activities,&nbsp;especially&nbsp;antitumor,&nbsp;antibacterial,&nbsp;antifungal,&nbsp;antimalarial,&nbsp;antiviral,&nbsp;anti-inflammatory&nbsp;and&nbsp;antileishmanial&nbsp;properties.&nbsp;Because&nbsp;of&nbsp;their&nbsp;effectiveness&nbsp;against&nbsp;various&nbsp;cancer&nbsp;cells,&nbsp;the&nbsp;triazine&nbsp;ring&nbsp;forms&nbsp;the&nbsp;backbone&nbsp;of&nbsp;some&nbsp;commercially&nbsp;vailable&nbsp;cancer&nbsp;drugs.&nbsp;Altreatamin,&nbsp;approved&nbsp;by&nbsp;FDA&nbsp;in&nbsp;1990,&nbsp;was&nbsp;the&nbsp;first&nbsp;s-triazine&nbsp;derivative&nbsp;drug&nbsp;used&nbsp;to&nbsp;treat&nbsp;ovarian&nbsp;cancer.&nbsp;Subsequently,&nbsp;various&nbsp;cancer&nbsp;drugs&nbsp;containing&nbsp;the&nbsp;s-triazine&nbsp;skeleton,&nbsp;such&nbsp;as&nbsp;Tretamin,&nbsp;Enasidenib&nbsp;and&nbsp;Gedatolisib,&nbsp;were&nbsp;approved&nbsp;and&nbsp;put&nbsp;into&nbsp;use.</p><p> The&nbsp;aim&nbsp;of&nbsp;the&nbsp;project&nbsp;is&nbsp;to&nbsp;synthesize&nbsp;a&nbsp;new&nbsp;derivative&nbsp;of&nbsp;the&nbsp;drug&nbsp;Gedatolisib&nbsp;(containing&nbsp;s-triazine&nbsp;and&nbsp;morpholine),&nbsp;used&nbsp;in&nbsp;cancer&nbsp;treatment,&nbsp;that&nbsp;contains&nbsp;functional&nbsp;groups&nbsp;capable&nbsp;of&nbsp;enhancing&nbsp;its&nbsp;antitumor&nbsp;activity.</p><p> In&nbsp;the&nbsp;first&nbsp;step,&nbsp;starting&nbsp;from&nbsp;cyanuric&nbsp;chloride,&nbsp;a&nbsp;chlorine&nbsp;group&nbsp;was&nbsp;replaced&nbsp;by&nbsp;a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;–NH₂&nbsp;group&nbsp;using&nbsp;NH₄OH,&nbsp;followed&nbsp;by&nbsp;morpholine&nbsp;ring&nbsp;substitution&nbsp;reactions&nbsp;with&nbsp;the&nbsp;second&nbsp;and&nbsp;third&nbsp;chlorines.&nbsp;In&nbsp;the&nbsp;final&nbsp;step,&nbsp;the&nbsp;target&nbsp;molecule&nbsp;was&nbsp;synthesized&nbsp;in&nbsp;the&nbsp;presence&nbsp;of&nbsp;2-fluorobenzoic&nbsp;acid&nbsp;and&nbsp;DCC&nbsp;(dicyclohexylcarbodiimide).&nbsp;The&nbsp;new&nbsp;compound&nbsp;was&nbsp;characterized&nbsp;FTIR,&nbsp;¹H&nbsp;and&nbsp;¹³C&nbsp;NMR.</p><p></p><p>Key&nbsp;words:&nbsp;Antitumor&nbsp;activity,&nbsp;s-triazine,&nbsp;morpholine,&nbsp;Gedatolisib</p>

View details